1. Lifelong monitoring of graft function, immunosuppressive levels, and screening for drug toxicity is required in all liver recipients.
T he success of liver transplantation has resulted in an ever-increasing number of patients who have undergone successful liver grafting and who are in need of long-term follow-up monitoring. Indeed, some 40,000 patients in the United States have undergone liver transplantation in the past decade, and approximately 5,000 additional patients per year will receive hepatic grafts in the United States. 1 Today, survival after liver transplantation is 90% at 1 year and approximately 75% at 5 years. The advent of living donor liver transplant in adults will add to the number of patients requiring long-term follow-up. 2 Because hepatic allograft dysfunction may occur any time after liver transplantation, lifelong monitoring of graft function seems inevitable. 3 In addition, continuous monitoring of immunosuppressive drug levels and screening for potential side effects related to these drugs remains an important part of the long-term management of the liver recipient. With the ever-increasing use of new immunosuppressive agents, the need for such monitoring appears to be increasing and is usually performed by the transplant surgeon and/or transplant hepatologist at the center in which the patient underwent the transplant procedure.
While the incidence and etiology of hepatic allograft dysfunction has been shown to be dependent on the time from the transplant procedure, for purposes of classification and discussion we have arbitrarily classified hepatic allograft dysfunction by time into two categories: (1) early allograft dysfunction Յ2 months following liver transplantation, and (2) late hepatic allograft dysfunction Ͼ2 months following liver transplantation, which will be emphasized in this review.
Monitoring for Hepatic Allograft Dysfunction
Monitoring for hepatic allograft dysfunction, in general, is most intense during the initial 2 weeks posttransplantation, when hepatic allograft rejection is most common. However, once the patient is dismissed from the hospital, there is a tendency to reduce the frequency of graft monitoring as the patient moves further from the transplant procedure. Reasons for reduced monitoring include inconvenience to the patient and attempts to reduce overall costs. In the Mayo Clinic program, we use the following protocol to monitor patients after liver transplantation. We obtain a complete blood count, serum levels of alanine aminotransferase (ALT), alkaline phosphatase, bilirubin, and creatinine, along with a trough level of the calcineurin inhibitor which is being used. Our schedule is as follows: (1) 1st week: daily laboratory tests obtained; (2) 2nd week: laboratory tests obtained three times per week; (3) 3rd and 4th weeks: laboratory tests obtained twice per week; (4) 2nd, 3rd, and 4th months: laboratory tests performed on a weekly basis; and (5) 5th and 6th months: laboratory testing performed twice per month. From the 7th month onward, laboratory tests are obtained every 3 weeks and, after 1 year, at monthly intervals. However, it should be noted that should major changes occur in immunosuppressive therapy (e.g, if one of the immunosuppressive agents is being withdrawn or discontinued), we again perform laboratory monitoring weekly for at least 1 month after the immunosuppressive change. In addition, those recipients who have recurrent hepatitis C or who have had multiple rejection episodes are followed more closely depending on the clinical situation. It should be noted that the above guidelines used at the Mayo Clinic are based on our personal experience. Unfortunately, there are no objective data to guide us as to the optimal cost-effective means of monitoring for graft dysfunction in the liver transplant recipient. This clearly is an area in which further data are needed, particularly in the present era in which cost reduction is becoming of increasingly important. 4 
Defining Hepatic Allograft Dysfunction
In general, hepatic allograft dysfunction is defined as increasing or persistent elevations in serum levels of alanine aminotransferase, alkaline phosphatase, or bilirubin (greater than two times the upper limit of normal). Should such persistent abnormalities be detected, further evaluation with ultrasonography using doppler assessment of the hepatic vasculature, liver biopsy, and cholangiography are indicated to evaluate the cause of graft dysfunction. Because the pattern of hepatic enzyme elevations is frequently not helpful in determining the cause of hepatic allograft dysfunction, liver biopsy plays an important role and should be used liberally, but judiciously, in detecting the cause of late hepatic allograft dysfunction. This is important since immunosuppressive management strategy often depends on histologic findings and helps avoid the indiscriminate use of bolus intravenous corticosteroid therapy, which may prove detrimental to patients who have recurrent hepatitis B or C or those who have an infectious etiology causing hepatic allograft dysfunction such as cytomegalovirus infection. Furthermore, bolus corticosteroid therapy is often complicated by glucose intolerance often requiring insulin therapy and the need for hospitalization. For these reasons, we believe the indiscriminate use of high-dose bolus corticosteroid therapy should be avoided if possible; thus, an accurate diagnosis of the cause of hepatic allograft dysfunction is important.
Causes of Late Hepatic Allograft Dysfunction
Late hepatic allograft dysfunction may result from a variety of causes including rejection, vascular stenosis/ thrombosis, de novo or recurrent infection, biliary complications including stricture or stenosis, recurrent disease related to autoimmune mechanisms such as that seen in primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune chronic active hepatitis. In addition, drug hepatotoxicity must be excluded, and the development of neoplasms such as a posttransplant lymphoproliferative disorder or the recurrence of hepatocellular carcinoma are important considerations (Table 1) .
Diagnostic Approach to Late Hepatic Allograft Dysfunction
In all cases of late hepatic allograft dysfunction, the approach to diagnosis includes a number of steps (Table  2) . This assessment includes a review of the following: (1) the original liver disease which resulted in liver In addition to a thorough review of the patient's history, viral hepatitis serologies and autoimmune markers should be obtained and an ultrasound with Doppler studies of the graft's vasculature should be performed. If the ultrasonography examination shows evidence for hepatic artery thrombosis, an angiogram should be performed to confirm this diagnosis, and the patient should be considered for retransplantation. If bile duct dilatation is seen on ultrasonography study, a cholangiogram should be performed to assess the biliary tree and to intervene if appropriate. If the ultrasonography studies are negative, a liver biopsy should be performed to assess for rejection or recurrence of disease. If a diagnosis is made, appropriate treatment should be instituted. If the liver biopsy findings are nonspecific or shows evidence of bile duct proliferation or bile duct obstruction, the liver biopsy should be followed up with cholangiographic studies. This approach is outlined in Figure 1 .
Rejection
Acute cellular rejection is diagnosed in 30% to 60% of liver recipients and typically occurs within the first 30 days following liver transplantation. 5 Indeed, 85% of acute rejection episodes will occur within the first 28 days (Fig. 2) . The diagnosis is made exclusively by liver biopsy, and 80% to 90% of acute rejection episodes will respond to high-dose intravenous bolus corticosteroid therapy.
Late acute rejection episodes occurring greater than 30 days posttransplant occur in 15% to 20% of recipients and are often related to a reduction or withdrawal of immunosuppressive medications, erratic absorption of immunosuppressive agents, or to poor compliance, which occurs particularly in the teenage population. 6 Because monitoring for hepatic allograft dysfunction is less frequent the further one is removed from liver transplantation, late acute rejection episodes are frequently associated with a delay in diagnosis and, therefore, are less responsive to bolus corticosteroid therapy and often require antilymphocyte therapy to control. Patients at highest risk for developing acute rejection include those less than 30 years of age, recipients who have undergone liver transplantation for an autoimmune liver disease or for acute fulminant hepatic failure, and those who have Child's class A disease at the time of transplantation. 5, 7, 8 Recipients less likely to reject include those who are greater than 60 years of age, those who have alcoholic liver disease as their underlying indication for liver transplantation, and those patients who have Child's class C disease at the time of transplantation. 5 Finally, the primary immunosuppressive regimen used posttransplantation seems to determine the overall incidence of rejection, with patients on tacrolimus-related regimens having less rejection than patients receiving cyclosporine-based immunosuppressive regimens (Fig. 3) . 9 Current studies indicate that the combination of tacrolimus and sirolimus was associated with acute rejection rates as low as 14%. 10 Thus, over the past decade, as immunosuppressive therapy has improved and our understanding of rejection has evolved, the incidence of rejection seems to be slowly decreasing.
Because acute rejection can occur at any time after liver transplantation and it remains a histologic diagnosis, liver biopsy is essential in evaluating liver transplant recipients who have hepatic allograft dysfunction. Important information is obtained from the liver biopsy which helps determine management strategies. This becomes particularly important in patients who have hepatitis C as their underlying liver disease, because rejection has been shown to have a major deleterious effect on the long-term course of recurrent hepatitis C. 11, 12 Chronic rejection, on the other hand, has been decreasing over the past decade, with most transplant centers reporting less than a 4% incidence of this serious complication. 13, 14 The reason for the decrease in 
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chronic rejection seems multifactorial, but is clearly related to improvement in immunosuppressive agents, widespread use of liver biopsy in evaluating hepatic allograft rejection, and the increased ability of the histopathologist to diagnose chronic rejection at an earlier stage, which allows for effective changes in immunosuppressive therapy. 15 Chronic rejection is almost always preceded by one or more episodes of acute rejection that are often resistant to bolus intravenous corticosteroid therapy and require antilymphocyte therapy. The late stages of chronic rejection are characterized by profound cholestasis in which interlobular and septal bile ducts are absent from most portal tracts. 16 
Vascular Complications
Vascular complications after liver transplantation include hepatic artery, portal vein, and hepatic vein stenosis and thrombosis. Hepatic artery complications are the most common vascular complications and occur in 5% to 12% of adult liver recipients. Hepatic artery thrombosis is the most common, occurring in approx- 
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imately 7% of adult recipients and in 10% to 40% of pediatric recipients. 17 Hepatic artery thrombosis generally occurs early (Ͻ30 days posttransplant), but a recent report has noted a 2.8% incidence of late hepatic artery thrombosis occurring more than 4 weeks after transplant. 18 Risk factors for hepatic artery thrombosis include small hepatic arterial size, complex anatomy, use of extension grafts for the arterial anastomosis, hypercoagulable state, dehydration, prolonged ischemic time, and primary sclerosing cholangitis as an underlying liver disease. 18, 19 Furthermore, cigarette smoking has been associated with the occurrence of late hepatic artery thrombosis. 19 In those patients who developed late hepatic artery thrombosis (Ͼ1 month after transplantation), clinical findings usually include biliary stricturing often associated with bacterial cholangitis and, less frequently, hepatic abscess formation. Graft failure after hepatic artery thrombosis is usually eminent and retransplantation is usually required.
In one series, hepatic artery stenosis has been reported to occur in 5% of recipients. 20 The median time to diagnosis was 100 days (range, 1 to 1,220 days). No risk factors were identified and treatment included resection of the stenotic segment with primary reanastomosis or percutaneous transluminal balloon angioplasty. At a mean follow-up period of 25 months, 67% of patients were asymptomatic with satisfactory graft function. Patient and graft survival at 4 years in patients with revised hepatic arteries has been reported to be 65% and 56%, respectively.
The second most common vascular complication is portal vein thrombosis/stenosis. 21 These patients often present with refractory ascites, recurrent variceal bleeding, and/or encephalopathy. However, occasionally patients with portal vein thrombosis have been known to present with asymptomatic liver test abnormalities. 21 Patients at risk for portal vein thrombosis include recipients with portal vein thrombosis occurring in their native liver, patients who require interposition grafting for the portal vein anastomosis, and those who have had previous portocaval shunt surgery. Patients who have a hypercoagulable state are also prone to develop post liver transplant portal vein thrombosis. Those patients with portal vein stenosis at the anastomosis may occasionally benefit from balloon dilatation and stenting, which may avoid surgical intervention or retransplantation.
Thrombosis or stenosis of the hepatic vein or the inferior vena cava remains an unusual complication. An exception to this statement occurs in patients undergoing liver transplantation for the Budd-Chiari syndrome. Hepatic vein stenosis associated with prolonged, refractory ascites has been described in patients in which the piggyback technique for the hepatic veininferior vena cava anastomosis was used. 22 Inferior vena cava (IVC) stenosis or thrombosis occurs more commonly in patients undergoing a conventional IVC anastomosis. A diagnosis can be made using Doppler ultrasonography and can be confirmed with venacavography or with the demonstration of a pressure gradient across the vena cava anastomosis. Treatment options range from radiologic balloon dilatation and surgical repair to, on occasion, retransplantation.
Biliary Complications
Biliary complications occur in up to 20% of patients after liver transplantation and remain a significant cause of posttransplant morbidity. 23 Furthermore, recent studies have suggested an increased incidence of biliary complications in patients receiving a reduced-size graft. 24 If the diagnosis of a biliary complication is entertained, an ultrasound of the liver and a Doppler study of the hepatic artery should be performed. Any suspicion of hepatic artery stenosis or thrombosis should be further evaluated with angiography. The absence of dilated bile ducts does not rule out biliary pathology because bile duct strictures frequently escape detection by ultrasonography. 25 Therefore, a cholestatic picture with a negative ultrasound examination requires either a liver biopsy or a cholangiogram, depending on the overall clinical scenario. In all cases in which biliary tract abnormalities are found after liver transplantation, hepatic artery thrombosis must be excluded.
Biliary complications include biliary leaks, anastomotic strictures, and nonanastomotic strictures. Biliary leaks usually occur early at the site of the bile duct 
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anastomosis. In addition, they often occur at the time the T-tube is removed. This latter complication can be prevented by not using a T-tube or by using a ureteral catheter placed through the donor cystic duct, which is held in place with a hemorrhoidal rubber band. This technique has significantly reduced the incidence of bile leaks at the time of biliary tube removal while allowing access to the biliary tree for purposes of cholangiographic assessment.
Anastomotic strictures are related to the creation of a surgical bile duct anastomosis and often can be treated with endoscopic therapy, including balloon dilatation or stenting. [26] [27] [28] Surgical intervention with conversion of the biliary anastomosis to a hepatic jejunostomy is required in some cases. 29 Nonanastomotic strictures unrelated to hepatic artery thrombosis have been found to be associated with a number of risk factors listed in Table 2 . Except for patients experiencing recurrent primary sclerosing cholangitis, nonanastomotic strictures usually occur in the initial 3 months after liver transplantation and are often related to ischemic damage at the time of harvesting. These strictures are often treated with endoscopic or percutaneous balloon dilatation and/or stenting. [26] [27] [28] However, approximately 20% of such nonanastomotic strictures are refractory or untreatable using endoscopic or percutaneous therapy because they involve the small intrahepatic bile ducts. In these situations, retransplantation may be necessary. In the long term, antibiotic treatment may reduce the incidence of bacterial cholangitis and may prolong graft survival.
Recurrence of the Original Disease
The most common cause of late hepatic allograft dysfunction is clearly related to the recurrence of the original disease (Table 1) . It is, therefore, important to be cognizant of the original liver disease for which the patient underwent liver transplantation when evaluating late hepatic allograft dysfunction. The most important liver disease recurring after liver transplantation is hepatitis C. Hepatitis C is the leading indication for liver transplantation in the United States, with approximately 40% of liver transplants being performed for this disease entity. It is also widely known that the hepatic allograft is universally reinfected with the hepatitis C virus (HCV). 30 While the early posttransplant survival rate for patients undergoing liver transplanta- 
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tion for HCV is similar to that of other indications, a decreased rate in patient and graft survival is now becoming apparent at 5 years posttransplant (Fig. 4) . Indeed, up to 28% of HCV-positive liver allograft recipients have been reported to develop cirrhosis by 5 years after liver transplantation. 31 A number of factors have been identified which have been associated with aggressive recurrence of HCV. These include high pretransplant viral load, the occurrence of acute rejection episodes requiring bolus corticosteroids or antilymphocyte therapy, the presence of HCV genotype 1a of 1b, HCV patients who have received organs from older donors, and the development of cytomegalovirus infection posttransplantation. [32] [33] [34] [35] [36] [37] In addition, one study has suggested that early recurrence and the severity of recurrence are both associated with a poor prognosis. 33 Recurrent hepatitis C can present as an acute hepatitis or, more commonly, has an insidious onset of abnormal liver tests in which portal hepatitis and/or fibrosis are shown on liver biopsy. 33 The diagnosis is made by demonstrating the presence of the HCV RNA in blood using polymerase chain reaction studies and by demonstrating classic findings on liver histology. It should be noted that differentiating acute rejection from recurrent hepatitis C remains a challenge and has important therapeutic implications. 38 Recent studies have shown a modest response to the combination of interferon and ribavirin therapy, with approximately 25% of patients with recurrent HCV showing a sustained virologic response 6 months after stopping therapy. [39] [40] [41] The identification of prognostic markers for hepatitis B virus (HBV) reinfection post liver transplantation has enabled the development of effective immunoprophylaxis (hepatitis B immunoglobulin [HBIG]), which has reduced HBV recurrence and dramatically improved patient and graft survival in HBV-infected recipients. 42, 43 Liver recipients, however, with active viral replication as evidenced by the presence of HBe antigen or HBV viral DNA (HBV DNA), have a higher rate of recurrence compared to recipients with hepatitis B who have neither marker of active replication. 44, 45 The introduction of the antiviral therapeutic agent lamivudine has also contributed to the prevention of recurrence of hepatitis B after liver transplantation. 46 HBV recipients receiving the combination of HBIG therapy and lamivudine have virtually eliminated recurrence of HBV disease. 47, 48 However, patients treated with long-term lamivudine alone have experienced the appearance of YMDD mutants in about one third of patients at the end of 2 years of treatment. 46, 49 However, adefovir has recently been shown to effectively treat the lamivudine-resistant hepatitis B mutants and, thus, may be useful in treating liver transplant recipients developing the YMDD mutant.
One final development has been the ability to use hepatitis B vaccination and to discontinue hepatitis B immune globulin therapy in long-term liver transplant recipients as reported in a single study. 50 However, all patients reported were nonreplicative both before and after transplantation, and it remains to be shown whether HBV vaccination can induce protective antibodies in high titer in patients with active HBV viral replication. 51 The recurrence of hepatitis B virus infection is diagnosed by showing the presence of HBV surface antigen or HBV DNA in the liver recipient's serum, as well as showing the presence of HBV surface antigen or core antigen in liver tissue. Molecular studies are necessary to diagnose the appearance of the YMDD, HBV mutant.
In addition to the recurrence of the original liver disease in patients undergoing liver transplantation for hepatitis B and C, a number of autoimmune liver diseases have been shown to recur after liver transplantation. Primary biliary cirrhosis (PBC) has been shown to recur in up to 20% of patients in most reported series and in up to 50% of patients in select series where follow-up has exceeded 10 years. [52] [53] [54] [55] Recently, a report has noted the recurrence of primary biliary cirrhosis after living donor liver transplantation. 56 However, because there is considerable histologic overlap between chronic rejection and recurrent PBC, the diagnosis can be challenging. However, patients with chronic rejection usually are distinguishable by having a history of multiple acute rejection episodes, which often differentiates patients with chronic rejection from those with recurrent PBC.
Primary biliary cirrhosis usually recurs 3 years or more after liver transplantation, but has been reported to recur earlier and with increased frequency in those patients immunosuppressed with tacrolimus. 57 To date, recurrence of primary biliary cirrhosis has had little impact on the overall quality of life and only rarely has retransplantation been required. Many centers use ursodeoxycholic acid to treat recurrence of primary biliary cirrhosis. However, its use is empiric and there are no data showing an overall beneficial impact on slowing disease progression after recurrence in liver transplant recipients.
Primary sclerosing cholangitis (PSC) has also been shown to recur in long-term follow-up studies. [58] [59] [60] [61] [62] [63] [64] A number of studies have suggested that PSC recurs in up to 20% to 30% of patients undergoing liver transplantation for PSC. Other liver transplant programs have reported an increase in the incidence of nonanastomotic strictures, which is the hallmark of recurrent PSC. Because other conditions, such as hepatic artery thrombosis, biliary ischemic injury, chronic rejection, ABO-incompatible allografting, and recurrent bacterial cholangitis can all be associated with both histologic and radiologic findings compatible with PSC, other causes of bile duct damage must be excluded before the diagnosis of recurrent PSC can be made.
Most cases of recurrent PSC are diagnosed 3 years or more posttransplantation, and the initial finding is a persistent elevation in serum alkaline phosphatase level or the finding of obliterative bile duct lesions on liver biopsy. The diagnosis should be suspected in patients who have undergone liver transplant for PSC and who have a persistent or rising serum alkaline phosphatase level. In our experience, 80% of patients who have a serum alkaline phosphatase persistently above 500 IU/L will have evidence of recurrent PSC if a cholangiogram is performed (Fig. 5) . The natural history of recurrent PSC remains undefined but, in general, it is a slowly progressive process leading to biliary fibrosis and, occasionally, the need for retransplantation. As in primary biliary cirrhosis, many centers use ursodeoxycholic acid to treat recurrent PSC. However, there is no data showing a positive impact in slowing disease progression.
Recurrence of autoimmune hepatitis after liver transplantation has also been reported in a number of studies. [65] [66] [67] [68] [69] Approximately 20% to 30% of patients undergoing liver transplantation for autoimmune hepatitis develop features of recurrent disease. Diagnostic criteria for recurrence of autoimmune hepatitis are similar to those used for nontransplant patients and include the combinations of biochemical, serologic, and histologic abnormalities and the response to corticosteroid therapy. Our most recent study has indicated a 17% incidence of recurrent autoimmune hepatitis, with the mean time to recurrence being 4.6 years following liver transplantation. Recurrence was asymptomatic in 4 of the 7 patients and was detected only by surveillance liver histology in 2 patients. Histologic changes were generally mild, and there was not progression to cirrhosis during the mean 4.9 years of observation from the time recurrence of disease was diagnosed. The 5-year patient survival rate was 86%, and survival rates were not significantly different between patients with and without recurrent disease.
Risk factors identified included HLA DR3 and HLA DR4, which occurred more commonly in patients with recurrence of autoimmune hepatitis than in those without. Other risk factors that have been associated with the development of recurrent autoimmune hepatitis include suboptimal immunosuppression, particularly steroid withdrawal, and duration of follow-up. Indeed, in many cases, recurrent autoimmune hepatitis appears to be related to the reduction or withdrawal of corticosteroids, and the biochemical and histologic features rapidly respond to increased corticosteroid therapy. However, there are cases where recurrent autoimmune hepatitis behaves more aggressively, progressing to cirrhosis and graft failure requiring retransplantation. Presently, the histologic finding of plasma cell infiltration in the portal triad has been the classic histologic feature; however, the present definition lacks specificity. The development of uniform criteria to diagnose recurrent autoimmune hepatitis is needed. 70 Other liver diseases that have been shown to recur after liver transplantation include nonalcoholic steatohepatitis. [71] [72] [73] [74] One recent report suggests the development of nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis in patients having the phenotype for nonalcoholic steatohepatitis-related cirrhosis. 75 Recurrence of nonalcoholic steatohepatitis generally follows a benign course but occasionally can progress to cirrhosis and graft failure.
Finally, a number of reports have suggested that alcoholic liver disease may recur in patients with heavy alcohol intake in the posttransplant course. 76 The occurrence of acute alcoholic hepatitis has been noted and, therefore, an inquiry should be made with regard 
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to alcohol consumption in patients presenting with late hepatic allograft dysfunction, particularly in patients who have undergone liver transplantation for alcoholic liver disease. Finally, we have recently shown recurrence of sarcoid liver disease 3 years after liver transplantation (personal observation).
Other Infections
Infections after liver transplantation are largely related to immunosuppressive therapy and usually occur early. However, they can occur anytime posttransplantation and can cause considerable hepatic allograft dysfunction. Approximately 50% of liver recipients experience a bacterial infection, most commonly within the first 2 weeks posttransplant and related to intravascular lines, wound infections, biliary tract leaks, and urinary tract infections. One must also be aware that certain antibiotics such as macrolide antibiotics like erythromycin can also be associated with cholestasis in the hepatic allograft. Bacterial infections are caused by Gram-negative or Gram-positive organisms, both of which can be associated with cholestasis. 77, 78 Histologically, these changes are characterized by bile ductular proliferation with prominent bile plugging, which usually resolve as the bacterial infection responds to antibiotic therapy. These changes differ from those seen in extrahepatic bile duct obstruction where the proliferating bile ductules are located within the portal connective tissue and bile plugging is uncommonly seen.
Fungal infections usually occur between 1 and 6 months after liver transplantation and are often associated with a high mortality rate. 77, 79 Risks for fungal infections include pretransplant renal failure and dialysis, retransplantation, prolonged operative time, high blood utilization in the transplant procedure, long-term broad spectrum antibiotic coverage, and cytomegalovirus (CMV) infection. Fungal infections also have a high propensity to infect vascular grafts, resulting in mycotic aneurysms and arterial rupture. It is reported that 75% of post liver transplant fungal infections are caused by Candida species, followed by Aspergillus, which causes about 20% of fungal infections. Invasive fungal disease should be considered in all liver recipients with unexplained allograft dysfunction or fever of unknown origin. In general, Candida infections occur earlier than other fungal infections, and colonization of mucocutaneous sites represents the primary risk factor.
CMV infections are also common in the post liver transplant course. 80 The majority of CMV infections occur between the 6th and 8th week post liver transplant. Of those who develop CMV disease, approximately 50% are documented to have CMV hepatitis. Seronegative recipients of seropositive donors have the highest risk of developing symptomatic CMV disease. It should be noted, however, that late CMV infection can be activated by the use of antilymphocyte antibodies, the use of cytotoxic drugs, treatment of a rejection episode, or systemic infections treated with long-term antibiotics. In addition to hepatitis, CMV also causes fever, leukopenia, thrombocytopenia, atypical lymphocytosis, pneumonitis, and retinitis. [80] [81] [82] Of note, serologic testing has little value in the diagnosis of CMV disease and the diagnosis is made using the shell-vial technique or by polymerase chain reaction (PCR) studies. 80 Histologically, typical nuclear inclusion bodies or microabscesses are noted on liver biopsy. In addition, CMV may be detected in tissue using PCR and immunohistochemical staining techniques.
Today, the use of prophylactic or preemptive treatment with ganciclovir or valganciclovir has markedly reduced the incidence of CMV disease. Of those who develop CMV disease, administration of intravenous ganciclovir for 2 to 4 weeks or until viremia clears is usually therapeutically successful. Resistant strains have been treated with foscarnet. Patients at high risk of developing CMV disease, such as those liver recipients receiving antilymphocyte therapy or those undergoing retransplantation, can reduce the risk of CMV infection by the prophylactic use of low-dose ganciclovir or valganciclovir. 83 Oral ganciclovir and valganciclovir have been shown to be safe and effective for use in CMV prophylaxis. 84 Other herpes viruses of importance include herpes simplex and the Epstein-Barr virus (EBV). Herpes simplex infections are commonly seen in the first 3 weeks after liver transplantation and can involve oral and genital mucosa, the eye, esophagus, and the liver. Herpes hepatitis can lead to serious allograft dysfunction and may lead to fulminant hepatic failure and death. The drug of choice for treating herpes simplex is acyclovir. Herpes simplex can virtually be eliminated by the prophylactic use of low-dose acyclovir (400 mg orally twice per day) for the first 6 weeks posttransplant and is widely used by many transplant centers.
The most common manifestations of EBV infection in liver transplant recipients include hepatitis and posttransplant lymphoproliferative disorders (PTLD). [85] [86] [87] [88] [89] EBV hepatitis usually occurs 4 to 6 months after liver transplantation and may be associated with over immunosuppression, particularly the use of antilymphocyte therapy. EBV may also be associated with PTLD and B-cell lymphoproliferative disorders. PTLD particularly involves the liver and may present initially with hepatic dysfunction. EBV infection and/or PTLD can occasionally lead to massive hepatic necrosis. EBV infection is diagnosed by detecting the presence of EBV virus using PCR technology. 90 In PTLD, the presence of the EBV genome usually signifies active EBV infection. Histologic features of PTLD can be similar to rejection, but a monomorphic mononuclear B-cell lymphocytic portal infiltrate without bile duct damage is highly suggestive of the diagnosis of PTLD. In situ immunohistologic screening for EBV can be useful in confirming the diagnosis. Unfortunately, effective antiviral agents are not available for prophylaxis or treatment of EBV infection. In patients with documented PTLD, withdrawal or marked decrease in immunosuppression may be helpful alone or in conjunction with chemotherapy, surgical resection, or radiation therapy.
Finally, in evaluating late hepatic allograft dysfunction, one must be aware of the development of de novo viral hepatitis A, B, or C. Liver transplant recipients are frequently vaccinated before transplantation for hepatitis A and B; however, most studies report that only 50% to 60% will develop antibodies. Furthermore, up to 70% of patients receiving a hepatitis B core-positive donor are at risk of developing acute hepatitis B infection after transplantation. 91 Therefore, patients receiving a hepatitis B core-positive donor organ should receive prophylactic treatment with HBIG and lamivudine. 92 Serologic studies to exclude active de novo viral hepatitis are important in the evaluation of late hepatic allograft dysfunction.
De Novo Autoimmune Hepatitis
A number of reports have now been published in which de novo autoimmune hepatitis has developed post liver transplantation. This finding has been reported in both adults and children. Patients who develop abnormal liver tests with a liver biopsy showing evidence of plasma cell, portal infiltration without evidence of duct damage in the presence of autoimmune markers should be suspected of having de novo autoimmune hepatitis. Treatment of this entity consists of increasing or restarting corticosteroid therapy. De novo autoimmune hepatitis has been reported particularly in patients who have been completely withdrawn from corticosteroid therapy. 93 
Recurrence of Hepatocellular Cancer
Hepatocellular cancer (HCC) is the most common primary hepatic malignancy and, in most instances, occurs in the setting of cirrhosis. In the United States, the incidence of hepatocellular cancer is increasingly related to the HCV epidemic. 94 The results of liver transplantation for HCC initially were poor and related to recurrence of the tumor. However, recent studies have suggested that select individuals with HCC and cirrhosis may achieve long-term survival comparable to those transplanted for other indications. Criteria indicating a good long-term prognosis include a single lesion (Ͻ5 cm) or multiple lesions (i.e., 3 lesions all Ͻ3 cm) without evidence of metastatic disease. 95 A number of studies have shown that HCCs that meet these requirements have less than a 25% recurrence at 5 years in patients undergoing liver transplantation. A recent report has suggested that these criteria may be extended to include solitary tumors less than 6.5 cm and those having 3 nodules, with the largest being less than 4.5 cm, without evidence of metastatic disease. In this study, patients meeting these criteria had survival rates of 90% and 75.2% at 1 and 5 years posttransplant, respectively. Thus, selection criteria for HCC remain in a state of evolution; however, distinct advances have been made in defining selection criteria to obtain reasonable results in patients with early stage HCC with cirrhosis. 96 
Drug Hepatotoxicty
Hepatic allograft dysfunction can occur secondary to drug therapy; therefore, a detailed drug-use history is essential in all liver transplant recipients presenting with late hepatic allograft dysfunction. 97 Although the relationship between the onset of symptoms and commencement of the drug may provide a clue to the presence of drug-related hepatotoxicity, it can sometimes be difficult if not impossible to completely exclude drug hepatotoxicity as a cause of hepatic allograft dysfunction. In many cases, the diagnosis of drug hepatotoxicity is one of exclusion after other possible causes of liver injury have been excluded. Drug-related hepatic injury is conventionally divided into cytotoxic (hepatocellular), cholestatic, and mixed patterns. Hepatic injury may or may not be accompanied by systemic manifestations of hypersensitivity such as fever, rash, and eosinophilia. Biochemical parameters frequently show hyperbilirubinemia associated with elevations in aminotransferase and alkaline phosphatase levels. The histologic picture caused by drug hepatotoxicity may be very nonspecific. Therefore, liver biopsy is sometimes not helpful in making a distinct diagnosis, but may be useful in excluding other causes of hepatic allograft dysfunction.
Medications commonly used in the transplant patient that may cause hepatotoxicity include azathioprine, trimethoprim-sulfamethoxazole, and antifungal agents such as amphotericin and ketoconazole. Macrolide antibiotics, such as erythromycin, have been associated with cholestatic hepatitis. Furthermore, lipidlowering agents that are frequently used in the liver transplant recipient can be associated with chronic liver enzyme abnormalities. If a drug is believed to be the cause of hepatic dysfunction, the offending drug must be immediately discontinued. Fortunately, most drug-induced hepatitis reverses upon reduction or discontinuation of the offending medication. However, it must be noted that hepatic injury may occasionally result in fulminant hepatic failure, which can lead to destruction of the hepatic allograft.
